Galera Therapeutics Expands Series B to $57 Million

Sofinnova Ventures joins existing lead investors NEA, Novartis Venture Fund and Novo Ventures

MALVERN, PENNSYLVANIA – November 28, 2016– Galera Therapeutics, Inc., a clinical-stage biotechnology company developing transformational new treatments for cancer patients, announced today it has received $15 million in funding from new investor Sofinnova Ventures, bringing its Series B financing total to $57 million. Sofinnova joins existing investors New Enterprise Associates, Novartis Venture Fund, Novo Ventures, … Continued

Galera Therapeutics Announces Presentation of One-year Follow-up Data From a Phase 1b/2a Study of GC4419 in the Reduction of Severe Oral Mucositis

Data Presented at the American Society of Radiation Oncology Annual Meeting

MALVERN, PA – September 27, 2016 – Galera Therapeutics, Inc., a clinical-stage biotechnology company developing new treatments for cancer patients, today announced the presentation of final data, including one-year tumor control, from a Phase 1b/2a clinical trial of GC4419, an investigational drug candidate for the reduction of severe chemoradiation-induced oral mucositis (OM), in an oral … Continued

Galera Therapeutics Announces Presentation at ASCO of Positive Results From Study of GC4419 for the Reduction of Severe Oral Mucositis

MALVERN, PA – June 6, 2016 – Galera Therapeutics, Inc., a clinical-stage biotechnology company developing new treatments for cancer patients, today announced the presentation of data from a Phase 1b/2a clinical trial of GC4419, an investigational drug candidate for the reduction of chemoradiotherapy-induced oral mucositis (OM), at the American Society of Clinical Oncology (ASCO) Annual … Continued

Galera Therapeutics Increases Series B Financing to $42 Million

Funding to Support Development of Clinical Stage Dismutase Mimetics in the Treatment of Cancer Patients

MALVERN, PA – February 3, 2016 – Galera Therapeutics, Inc., a clinical-stage biotech developing new treatments for cancer patients, announced today it has received an additional $5 million in funding from Enso Ventures to bring its Series B financing total to $42 million. Enso Ventures joins existing investors New Enterprise Associates, Novartis Venture Fund, Novo … Continued

Galera Therapeutics Announces Fast Track Designation of GC4419 for Prevention of Oral Mucositis

Enrolls First Patients in Late-Stage Trial of GC4419 in Head and Neck Cancer Patients

MALVERN, PA – January 7, 2016 – Galera Therapeutics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for GC4419, an investigational drug candidate, for the reduction of severity and incidence of radiation and chemotherapy induced oral mucositis (OM). Galera also announced today that it has begun enrolling … Continued

Galera Therapeutics Raises $37 Million in Series B Financing

Funding to Support Development of Clinical Stage Dismutase Mimetics in the Treatment of Cancer Patients

MALVERN, PA – October 14, 2015 – Galera Therapeutics, Inc., a clinical-stage biotech developing new treatments for cancer patients, announced today it has completed a $37 million Series B financing. The proceeds of the financing will be used to advance the development of Galera’s selective dismutase mimetics, including progressing lead candidate GC4419 into a Phase … Continued

Galera Therapeutics Raises $11 Million in Series A Financing

Funding to Support Clinical Development of Therapeutics for Fibrosis and Cancer
Galera Names Mel Sorensen, M.D. New President and CEO; Robert Beardsley, Ph.D., Executive Chair

MALVERN, Pa. and ST. LOUIS , Mo.– December 11, 2012 – Galera Therapeutics, Inc., a biotechnology company focused on the development of breakthrough drugs targeting oxygen metabolic pathways in cancer, fibrosis and other human diseases, today announced an $11 million Series A venture capital financing. The round is co-led by New Enterprise Associates (NEA) and … Continued